Fig. 1 | Scientific Reports

Fig. 1

From: Association of early vedolizumab trough levels with clinical, biochemical, endoscopic response and drug optimization during maintenance therapy in patients with inflammatory bowel diseases

Fig. 1

Boxplots of VTLs at W2, W6, and W14 according to outcome achievement among UC patients. Box plot illustrating the VTLs of responders and non-responders according to achievement of (A) W14 CSF-CREM at W2, (B–D) W14 BioRES[FC] at W2, W6, and W14, and (E–F) W14 EH at W2 and W6. BioRES, biochemical response; CSF-CREM, corticosteroid-free clinical remission; EH, endoscopic healing; FC, fecal calprotectin; UC, ulcerative colitis; VTL, vedolizumab trough level; W, weeks.

Back to article page